Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy.
Fabeni L, Alteri C, Berno G, Scutari R, Orchi N, De Carli G, Bertoli A, Carioti L, Gori C, Forbici F, Salpini R, Vergori A, Gagliardini R, Cicalini S, Mondi A, Pinnetti C, Mazzuti L, Turriziani O, Colafigli M, Borghi V, Montella F, Pennica A, Lichtner M, Girardi E, Andreoni M, Mussini C, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM; SENDIH Study group. Fabeni L, et al. Among authors: colafigli m. Sex Transm Infect. 2019 Dec;95(8):619-625. doi: 10.1136/sextrans-2019-054017. Epub 2019 May 10. Sex Transm Infect. 2019. PMID: 31076456
Interpretation systems for genotypic drug resistance of HIV-1.
De Luca A, Antinori A, Di Giambenedetto S, Cingolani A, Colafigli M, Perno CF, Cauda R. De Luca A, et al. Among authors: colafigli m. Scand J Infect Dis Suppl. 2003;106:29-34. doi: 10.1080/03008870310009623. Scand J Infect Dis Suppl. 2003. PMID: 15000579 Review.
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.
Svicher V, Alteri C, Montano M, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Callegaro AP, Capobianchi MR, Carosi G, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Pietro M, Di Santo F, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori C, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Manca G, Gargiulo F, Martinelli C, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Narciso P, Nozza S, Paolucci S, Pal G, Parisi S, Parruti G, Pignataro AR, Pollicita M, Quirino T, Re MC, Rizzardini G, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Vecchi L, Viscoli C, Vullo V, Zazzi M, Lazzarini A, Perno CF; DIVA group. Svicher V, et al. Among authors: colafigli m. New Microbiol. 2012 Jan;35(1):17-25. Epub 2012 Jan 10. New Microbiol. 2012. PMID: 22378549 Free article.
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A. Di Giambenedetto S, et al. Among authors: colafigli m. J Antimicrob Chemother. 2013 Jun;68(6):1364-72. doi: 10.1093/jac/dkt007. Epub 2013 Jan 30. J Antimicrob Chemother. 2013. PMID: 23372058
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Among authors: colafigli m. Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28. Scand J Infect Dis. 2014. PMID: 24161018 Clinical Trial.
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.
Fabbiani M, Zaccarelli M, Grima P, Prosperi M, Fanti I, Colafigli M, D'Avino A, Mondi A, Borghetti A, Fantoni M, Cauda R, Di Giambenedetto S. Fabbiani M, et al. Among authors: colafigli m. BMC Infect Dis. 2014 Jan 13;14:26. doi: 10.1186/1471-2334-14-26. BMC Infect Dis. 2014. PMID: 24418191 Free PMC article.
87 results